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CC BY-NC-ND license (http://creativAbstract Background/Purpose: Cardiovascular disease is the leading cause of mortality
among kidney transplant recipients. Carotid intima-media thickness (CIMT) of the common
carotid artery is a surrogate marker for early atherosclerosis. We wanted to compare the prev-
alence of increased CIMT among kidney transplant recipients with matched controls and its
association with clinical and laboratory parameters.
Methods: A comparative cross-sectional study involving kidney transplant recipients and
controls matched for age, sex, chronic kidney disease staging, and cardiovascular risks was
used. CIMT measurements were done using carotid ultrasound and considered increased if
>75th percentile matched for age- and sex-matched normal controls. Standard laboratory in-
vestigations, high sensitivity C-reactive protein, and asymmetric diamethylarginine were
analyzed.
Results: Thirty-six kidney transplant recipients (25 men, 11 women) with a median age of
41 years [interquartile range (IQR), 38e52 years] and 36 matched controls with a median
age of 44 years (IQR, 37e53 years) were enrolled. There were no demographic differences be-
tween the two groups. Kidney transplant recipients had a significantly increased CIMT, 0.8 mm
(IQR, 0.6e0.9) compared to matched-controls 0.55 mm (IQR, 0.5e0.7, p Z 0.001). Two thirds
of kidney transplant recipients had increased CIMT, which was associated with a higher low
density lipoprotein (LDL) (pZ 0.022) and higher hemoglobin (pZ 0.006). Smoking status
(pZ 0.058) and male sex (pZ 0.073) had a trend towards significance to increased CIMT.
Multiple linear stepwise regression demonstrated both age and hemoglobin were independent
predictors of CIMT (p < 0.001). We found no relationship between high sensitivity C-reactive
protein and asymmetric diamethylarginine with CIMT.of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak,
.
om (R.A. Cader).
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of Nephrology. Published by Elsevier (Singapore) Pte Ltd. This is an open access article under the
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CIMT in kidney transplant recipients 37Conclusion: CIMT among our kidney transplant recipients was significantly higher compared to
controls thereby increasing their cardiovascular risk.
背景: 心血管疾病是腎臟移植接受者的主要死因,總頸動脈的內膜中膜厚度 (CIMT) 則是早期動脈
粥樣硬化的替代性指標。在本研究中,我們比較了 CIMT 增厚於腎臟移植接受者與匹配對照組之間
的盛行率,並調查了 CIMT 與臨床及實驗室參數之間的關聯。
方法: 這是一項橫斷式比較性研究,涉及的對象包括腎臟移植接受者、及與其匹配 (年齡、性別、
慢性腎病分期及心血管風險) 的對照者。CIMT 以頸動脈超音波測量,增厚的定義為對應年齡性別
匹配正常對照組之 > 75th 百分位數。其他測量項目除了標準實驗室參數外,亦包括高敏感度 C-
reactive protein (hs-CRP) 及 asymmetric diamethylarginine (ADMA)。
結果: 分析對象包括 36位年齡中位數 41歲 (38,52) 之腎臟移植接受者 (25男、11女)及 36位年
齡中位數 44歲 (37,53)之匹配對照者,兩組間的人口學特徵並無不同。腎臟移植接受者之 CIMT為
0.8 mm (0.6,0.9 mm),明顯高於匹配對照者之 0.55 mm (0.5,0.7 mm) (pZ 0.001)。腎臟移植接受
者之間,3 分之 2 呈現 CIMT 增厚的情形,較厚的 CIMT 與較高的低密度脂蛋白 (p Z 0.022) 及較高
的血色素 (pZ 0.006)有關。吸煙狀況 (pZ 0.058)及男性性別 (pZ 0.073)亦有傾向與 CIMT增
厚有關。多變項線性逐步迴歸分析顯示,年齡及血色素均是CIMT的獨立預測因子 (p < 0.001)。對
於 CIMT 與 hs-CRP 或 ADMA 數值之間,我們並未發現明顯的關係。
結論: 在本研究的腎臟移植接受者中,CIMT 明顯高於對照組,因此具較高的心血管風險。Introduction
Kidney transplantation not only improves quality of life in
end-stage renal disease patients but also gives them a long-
term survival advantage by reducing their mortality risk
compared to maintenance dialysis.1 Cardiovascular disease
(CVD) is a major cause of morbidity and mortality in kidney
transplant (KTx) recipients and death from CVD is the com-
monest cause of graft loss.2 Although KTx recipients have a
lower risk of fatal and nonfatal cardiovascular events
compared to dialysis patients, their risk is much higher than
the general population.3 In addition to the traditional risk
factors, nontraditional risk factors that contribute to CVD in
KTx recipients include reduced kidney function post-
transplantation, longer dialysis duration prior to trans-
plantation, episodes of graft rejection, the effect of immu-
nosuppressive drugs, hyperhomocysteinemia, and elevated
levels of lipoprotein(a), C-reactive protein (CRP),
interleukin-6, and asymmetric dimethylarginine (ADMA).4e7
Accurate risk stratification of these patients will allow tar-
geted interventions to prevent or limit adverse outcomes.
Atherosclerotic structural changes as detected by high-
resolution B-mode ultrasound precede clinical findings by
several decades. Endothelial dysfunction has been shown to
be predictive of future cardiovascular events.8 Although
kidney function improves, endothelial dysfunction persists
after transplantation and the true mechanism is still poorly
understood.9 Carotid intima-media thickness (CIMT) of the
common carotid artery is a surrogate marker used to pre-
dict early atherosclerosis.9,10 The prevalence of subclinical
atherosclerosis measured by CIMT is greater in KTx re-
cipients compared to the general healthy population.3
Endothelial dysfunction and ongoing chronic inflammation
due to multiple risk factors including immunosuppressive
therapy play an important role towards premature sub-
clinical atherosclerosis in KTx recipients.11
Previous studies have compared KTx recipients with
healthy controls. Therefore, in our study we selected a
control group who are not only matched for age but also
CVD risk factors such as hypertension, diabetes mellitus,and staging of chronic kidney disease. We wanted to
compare CIMT between KTx recipients and non-KTx
matched controls and determine the factors influencing
the CIMT in KTx recipients.Methods
This was a comparative cross sectional study involving KTx
recipients at Universiti Kebangsaan Malaysia Medical Centre
(UKMMC), Kuala Lumpur, Malaysia, from January 2014 to
August 2014. The study was approved by the UKMMC Ethics
and Research Committee (Study Code FF-2014-022). All KTx
recipients attending the nephrology outpatient clinic at our
institution were screened. KTx recipients > 6 months post-
transplantation, aged  18 years and on stable triple
immunosuppressive therapy for > 6 months were included.
We excluded patients with documented CVD (ischemic
heart disease, stroke, peripheral artery disease) and any
patients who were pregnant. The matched control group
was selected from volunteers matched for age, sex, chronic
kidney disease staging, underlying hypertension, and dia-
betes mellitus from nephrology and medical clinics in
UKMMC. We excluded controls who were either pregnant,
had documented CVD, or were on any immunosuppressive
therapy.
After obtaining informed consent, history regarding
previous cardiovascular events (defined as any coronary
event such as myocardial infarction, angioplasty or coro-
nary artery bypass surgery, and cerebrovascular accident)
were obtained from patients’ medical records. Baseline
blood investigations for hemoglobin level, renal profile,
fasting blood sugar, glycated hemoglobin, and fasting lipid
profile were collected from both groups of patients. High-
sensitivity CRP (hs-CRP) and ADMA were collected only in
KTx recipients.
In addition to a mean of two seated blood pressure (BP)
readings, ambulatory BP monitoring was carried out in KTx
recipients using the BPRO machine (model T6400; Health-
stats, London, UK). BP readings were taken at 15-minute
38 R.A. Cader et al.intervals throughout the daytime and 30-minute intervals
during the night. Mean 24-hour daytime, night-time systolic
and diastolic BP, and mean arterial BP were derived from
24-hour ambulatory BP monitoring. For the control group, a
mean of two seated blood pressure readings was recorded
to ascertain their status of hypertension. Hypertension was
defined as systolic arterial pressure > 140 mmHg and/or
diastolic arterial pressure > 90 mmHg, or current use of
antihypertensive drugs prescribed with the aim to reduce
blood pressure.12
Diabetes mellitus was diagnosed according to the
American Diabetes Association and defined by a fasting
plasma glucose of  7mM or 2-hours postprandial glucose of
 11.1mM, or current use of antidiabetic agents.13
Measurement of CIMT of the right and left common ca-
rotid artery was performed as per protocol described in the
American Echocardiography Guidelines by a trained sonog-
rapher and verified by a consultant radiologist who was
blinded to the cases.10 Carotid ultrasound was performed by
high resolution B mode (Siemens SONOLINE G40, Siemens
Medical Solutions, USA) with a 7-MHz linear transducer and a
transducer aperture of 38 mm. The right and left carotid
arteries were scanned at the level of the bifurcation.10 The
mean from three readings was taken for ‘each side’ and the
maximum CIMT value was recorded for analysis. CIMT
values  75th percentile were considered increased and
indicative of increased CVD risk. As there is no local refer-
ence CIMT value for our general population, the matched
age and sex CIMT value from the Carotid Atherosclerosis
Progression Study (CAPS) was used.10
Statistical analysis
SPSS Version 20.00 (Chicago, IL, USA) was used and normality
testing was done for all study variables. Non-normallyTable 1 Demographic data and clinical characteristics for both
Characteristics Kidney transplant
nZ 36 (%)
Age (y) 41.5 (38.0,52.0)
Sex
Male 25 (69.4)
Female 11 (30.6)
Race
Malay 9 (25.0)
Chinese 26 (72.2)
Indian 1 (2.8)
Smokers 4 (11.1)
Hypertension 29 (80.6)
Systolic BP (mmHg) 135 (127e137)
Diastolic BP (mmHg) 78 (69e85)
Mean arterial pressure 96 (88e101)
Diabetes mellitus 12 (33.3)
CKD staging
Stage I 4 (11.1)
Stage II 25 (69.4)
Stage III 6 (16.7)
Stage IV 1 (2.8)
Data are presented as n (%) or mean (interquartile range).
BP Z blood pressure; CKD Z chronic kidney disease.distributed parameters are expressed as median (inter-
quartile range) and analyzed using nonparametric tests
(ManneWhitney U or KruskaleWallis test) for quantitative
variables. Categorical variables were analyzed using chi-
square tests. Correlations were tested using Spearman cor-
relation coefficients. Univariate and multivariate analyses
were performed using multiple linear and binary logistic
regression. Significance was taken as p < 0.05. Our sample
size to power the study at 80% was 36 patients in each arm.14Results
Forty-six KTx patients were screened but eight had docu-
mented ischemic heart disease and hence excluded. Two
patients defaulted follow-up and therefore only 36 KTx
recipients and 36 controls were included in the final
analysis.
There were no significant differences between KTx re-
cipients and the controls in demographic characteristics
and cardiovascular risks as shown in Table 1. Of the 36 KTx
recipients, 29 (80.6%) had a live donor transplant. All pa-
tients were on triple immunosuppressive therapy with ma-
jority on calcineurin inhibitors. Ten patients were on a
proliferative signal inhibitor. The causes of end-stage renal
disease were glomerulonephritis (nZ 14), diabetic ne-
phropathy (nZ 6), unknown cause (nZ 6), and hyperten-
sive nephrosclerosis (nZ 2). The KTx recipients body mass
index was 24.0 (20.7e26.3) kg/m2. Their dialysis duration
prior to transplantation was 18.5 (9.0e28.9) months and
duration post renal transplantation was 76.5 (48.0e108)
months. Table 2 shows the laboratory characteristics of KTx
recipients.
KTx recipients had a significantly increased CIMT 0.80
(0.60e0.90) mm compared to controls 0.55 (0.50e0.70) mmgroups.
Control
nZ 36 (%)
p
44.5 (37.3,53.5) 0.790
25 (69.4) >0.999
11 (30.6)
16 (44.4) 0.089
17 (47.2)
3 (8.4)
6 (16.7) 0.121
29 (80.6) >0.999
130 (117e140) 0.749
83 (69e90) 0.504
100 (86e103) 0.712
12 (33.3) <0.999
4 (11.1) >0.999
25 (69.4)
6 (16.7)
1 (2.8)
Table 2 Laboratory characteristics of kidney transplant
recipients.
Parameters Median (IQR)
Hemoglobin (g/dL) 13.1 (11.9e14.0)
Hematocrit (%) 40.6 (37.2e43.4)
Creatinine (mM) 109.5 (89.5e121.3)
Estimated GFR (mL/min/1.73m2) 67.5 (60.0e80.0)
Fasting blood sugar (mM) 5.2 (4.62e7.05)
HbA1C (%) 5.95 (5.40e6.93)
Low density lipoprotein (mM) 2.47 (1.94e3.01)
High density lipoprotein (mM) 1.56 (1.30e1.75)
Triglycerides (mM) 1.37 (1.03e1.84)
Total cholesterol (mM) 4.65 (4.10e5.54)
Urine protein creatinine
index (g/mmol)
0.02 (0.01e0.03)
High-sensitivity C-reactive
protein (mg/L)
0.65 (0.13e1.93)
Asymmetric dimethylarginine (mM) 0.94 (0.81e1.20)
GFR Z glomerular filtration rate; HbA1C Z glycated hemoglo-
bin; IQR Z interquartile range.
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increased CIMT were predominantly diabetic and had a
higher BP. Their median CIMT in the diabetic patients was
0.7 (0.53e0.98) mm compared to the nondiabetics 0.5
(0.4e0.6) mm, (pZ 0.01). The control group patients with
increased CIMT had a median systolic blood pressure of 142
(138e151) mmHg whereas in the normal CIMT group was
128 (115e135) mmHg, (pZ 0.006). We also found a strong
correlation between systolic blood pressure and CIMT
thickness in the control group (R2 Z 0.444, p < 0.001).
In the KTx recipients, we compared clinical and labo-
ratory parameters in patients with and without increased
CIMT as shown in Table 3. On univariate analysis, we found
age (R2 Z 0.566, p < 0.001) and hemoglobin (R2 Z 0.395,
pZ 0.017) positively correlated with CIMT measurement.
There was a significant correlation between ADMA and hs-
CRP (R2 Z 0.352, pZ 0.036). On multiple linear stepwise
regression we used age and hemoglobin on the prediction
model with two steps (Table 4).Discussion
Endothelial dysfunction and ongoing chronic inflammation
due to multiple risk factors including immunosuppressive
therapy play an important role in premature subclinical
atherosclerosis in KTx recipients.4,11,15 We found that the
prevalence of increased CIMT was significantly higher in our
KTx recipients compared to controls. These findings concur
with Basiratnia et al14 who demonstrated a higher mean
CIMT in KTx recipients compared to healthy individuals.
However Basiratnia et al14 looked at healthy controls,
whereas in our study, our controls were matched for CKD
staging and CVD risk. We found no difference in terms of
blood pressure, or diabetes or dyslipidemia between our
controls and KTx recipients that could contribute to CIMT.
Apart from diabetes, hypertension, and age, there are
other factors that play a role in aggravation of theatherosclerosis in our KTx recipients. These could be due to
their immunosuppressive therapy, microinflammation, and
some effects from dialysis vintage.
Our study is the first to evaluate the prevalence of
subclinical atherosclerosis by measuring CIMT among KTx
recipients in Malaysia. The majority of our KTx recipients
had increased CIMT and this is in keeping with several other
studies.16,17
Kasiskeet al18 reported that 16% of KTx patients developed
new atherosclerotic complications over a 10-year period and
was independently associated with increasing age, male sex,
cigarette smoking, the presence of diabetes mellitus, hy-
pertension, and elevated serum cholesterol. Similarly, we
observed that KTx recipientswith increased CIMThad a higher
low density lipoprotein (LDL), higher hemoglobin, and a
shorter duration of dialysis. We also found male sex and
smoking to have a trend towards significance.
Hypertension plays an important role in the develop-
ment of atherosclerosis with studies demonstrating its as-
sociation with increased CIMT.19,20 We could not establish
this association in our study due to the good blood pressure
control in our KTx recipients and the small sample size. The
high prevalence of hypertension in our study could be
explained by pre-existing hypertension and the use of cal-
cineurin inhibitors and steroids as part of maintenance
immunosuppression.21
Dyslipidemia, a frequent and persistent complication
after solid organ transplantation, contributes to cardio-
vascular morbidity and mortality. The pathogenesis of post-
transplantation dyslipidemia is not fully understood,
although several factors including age, weight, pre-
transplantation lipid levels, and immunosuppressive ther-
apy, in particular corticosteroid, cyclosporine, and
proliferative signal inhibitors, are implicated.22 Our pa-
tients with increased CIMT had a significantly higher LDL
compared to those with normal CIMT and in keeping with
the reported literature.16,23 Artz et al24 demonstrated an
improvement in CVD risk profile (especially lipid profile)
after switching KTx recipients from cyclosporine A to
tacrolimus.
Our KTx recipients with increased CIMT had a higher
hemoglobin, consistent with Toz et al.25 We believe the
association between higher hemoglobin and increased CIMT
in our study could also be contributed by smoking and is
consistent with several other studies.20,26 The smokers had
a trend (pZ 0.058) towards increased CIMT over non-
smokers with the four current and former smokers having a
hemoglobin >15 g/dL. On further analysis, we found that
the smokers had significantly higher hemoglobin than non-
smokers, pZ 0.04. Cigarette smoking after kidney trans-
plantation has been associated with adverse cardiovascular
outcomes and allograft dysfunction.27
In contrast to Massy,22 we found patients with a shorter
duration of dialysis had increased CIMT. On further sub-
analysis, the majority of transplant patients who had dial-
ysis for <2 years were males with dyslipidemia,
hypertension and diabetes. We believe that these could
have confounded our findings.
KTx recipients are believed to have a persistent low-
grade inflammation that contributes to the endothelial
dysfunction. Inflammation is increasingly recognized as a
modifiable cardiovascular risk factor in renal disease.4
Table 3 Comparison among kidney transplant recipients with increased and nonthickened carotid intima-media thickness
(CIMT).
Parameters Thickened CIMT
n Z 24
Nonthickened
CIMT
n Z 12
p
Age (y) 43.49 (38.25e51.5) 41.00 (33.75e63.50) 0.856
Sex
Male 19 (52.8) 6 (16.7) 0.073
Female 5 (13.9) 6 (16.7)
Smoking status
Current smokers 4 (11.1) 0 (0) 0.058
Former smokers 4 (11.1) 0 (0)
Never smokers 16 (44.4) 12 (33.3)
Diabetes mellitus 8 (66.7) 4 (33.3) > 0.999
Hypertension 18 (50) 11 (30.6) 0.234
Blood pressure (mmHg)
Systolic 135 (127e137) 125 (114e146) 0.416
Diastolic 78 (69e85) 77 (63e89) 0.631
Mean arterial pressure 96 (88e101) 96 (79e104) 0.608
CKD staging
Stage I 2 (5.6) 2 (5.6) 0.173
Stage II 19 (52.8) 6 (16.7)
Stage III 2 (5.6) 4 (11.1)
Stage IV 1 (2.8) 0 (0)
Types of donor
Living 19 (52.8) 10 (27.8) 0.766
Cadaveric 5 (13.9) 2 (5.6)
Duration of dialysis (mo) 18 (7.5e24) 30 (16.5e42) 0.041
Duration post transplantation (mo) 82 (47e108) 76 (57.5e118) 0.882
Creatinine (mM) 111 (91.8e121.3) 104.5 (75.5e124) 0.562
Estimated GFR (mL/min/1.73m2) 67 (60.5e79.8) 75 (52.3e85.3) 0.886
Hemoglobin (g/dL) 13.75 (12.25e14.55) 12.35 (11.43e12.99) 0.006
HbA1C (%) 5.85 (5.32e6.92) 6.05 (5.45e6.93) 0.655
Fasting blood sugar (mM) 5.15 (4.65e7.58) 5.35 (4.62e6.95) 0.830
Total cholesterol (mM) 4.86 (4.37e5.91) 4.49 (3.77e5.34) 0.156
Low density lipoprotein (mM) 2.58 (2.10e3.29) 1.96 (1.53e2.65) 0.022
High density lipoprotein (mM) 1.57 (1.30e1.99) 1.53 (1.23e1.70) 0.476
Triglycerides (mM) 1.41 (0.92e1.79) 1.31 (1.03e2.40) 0.753
Urine PCI (g/mmol) 0.02 (0.01e0.03) 0.03 (0.01e0.03) 0.379
Hs-CRP (mg/L) 0.95 (0.53e2.75) 0.30 (0.10e1.65) 0.188
ADMA (mM) 0.96 (0.93e1.27) 0.94 (0.77e1.17) 0.280
Data are presented as n (%) or mean (interquartile range).
Values in bold indicate significant difference (p <0.05).
ADMAZ asymmetric dimethylarginine; CKDZ chronic kidney disease; GFRZ glomerular filtration rate; HbA1CZ glycated hemoglobin;
Hs-CRP Z high-sensitivity C-reactive protein; PCI Z protein creatinine index.
40 R.A. Cader et al.Studies have reported that several inflammatory markers
(hs-CRP, interleukin-1 and 6, and tumor necrosis factor-a)
are increased in KTx recipients.4 However, we could not
demonstrate any association between hs-CRP and CIMT due
to the small sample size.Table 4 Multiple linear regression.
Model Dependent variable Independent variables
1 CIMT value Age
2 CIMT value Age
Hemoglobin
CIMT Z carotid intima-media thickness.On univariate analysis, we demonstrated a positive
correlation of increasing age with CIMT. This is consistent
with several large studies including CAPS where increasing
age has been associated with progression of atheroscle-
rosis.10 Aging-related mechanical and structural changes ofR2 p R2 change p
0.211 0.005
0.398 <0.001 0.211 0.005
0.187 0.003
CIMT in kidney transplant recipients 41the vascular wall cause loss of arterial elasticity, reduced
arterial compliance, hardening, and stiffening of the
vessel. Subsequent multiple linear regression analysis
demonstrated age and hemoglobin to be the main inde-
pendent predictors of CIMT.
We did not have baseline CIMT measurements pre-
transplantation to establish significant progression of sub-
endothelial dysfunction. Our small sample size was the
main limitation that may cause bias in our results. Another
limitation in our study was the reference for normal values
of CIMT. As there are limited data among the East Asian
population, we had to resort to the use of CAPS for refer-
ence, which is derived from Caucasians who have dissimilar
sociodemographic and genetic background from Asians.10
We feel that we may have underestimated the cardiovas-
cular risk in our patients.
In conclusion, our study demonstrated a higher preva-
lence of increased CIMT among KTx recipients compared
with matched (age, sex, CKD staging, and CVD risk) con-
trols. Age and hemoglobin were important independent risk
predictors for increased CIMT. More than half of our KTx
recipients are at increased risk of cardiovascular disease
and a multitargeted approach is important to reverse the
progression of atherosclerosis. Larger prospective studies
are indicated to establish better association between all
the cardiovascular risks with CIMT in KTx recipients.Conflicts of interest
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